John A. Lewicki - Jun 21, 2024 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role
Chief Scientific Officer
Signature
/s/ Christine Fox, by power of attorney
Stock symbol
MREO
Transactions as of
Jun 21, 2024
Transactions value $
$0
Form type
4
Date filed
6/25/2024, 06:21 PM
Previous filing
Jan 26, 2024
Next filing
Jun 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MREO American Depositary Shares representing Ordinary Shares Options Exercise $0 +69K +1723.71% $0.00 73K Jun 21, 2024 Direct F1, F2
holding MREO American Depositary Shares representing Ordinary Shares 14.2K Jun 21, 2024 By The Lewicki Family Living Trust dated December 6, 2000 F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MREO Performance Based Restricted Stock Unit Options Exercise $0 +69K $0.00 46K Jun 21, 2024 American Depository Shares 69K $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2 Represents performance-based restricted stock unit ("PSU") earned under the issuer's 2019 Employee Incentive Plan (the "Plan") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025).